Cargando…

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy

Breast cancer guidelines advise sentinel lymph node biopsy (SLNB) in patients with ductal carcinoma in situ (DCIS) on core biopsy at high risk of invasive cancer or in case of mastectomy. This study investigates the incidence of SLNB and SLN metastases and the relevance of indications in guidelines...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Roozendaal, L. M., Goorts, B., Klinkert, M., Keymeulen, K. B. M. I., De Vries, B., Strobbe, L. J. A., Wauters, C. A. P., van Riet, Y. E., Degreef, E., Rutgers, E. J. T., Wesseling, J., Smidt, M. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837213/ https://www.ncbi.nlm.nih.gov/pubmed/27083179 http://dx.doi.org/10.1007/s10549-016-3783-2

Ejemplares similares

Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast
por: Jia, Huiqing, et al.
Publicado: (2022)

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients
por: Goorts, Briete, et al.
Publicado: (2017)

Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis
por: Ploumen, Roxanne A. W., et al.
Publicado: (2023)

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance
por: Viale, Giuseppe, et al.
Publicado: (2016)

Sentinel lymph node biopsy of the internal mammary chain in breast cancer
por: Postma, E. L., et al.
Publicado: (2012)

Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study
por: van Roozendaal, Lori M., et al.
Publicado: (2016)

A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone
por: Rakovitch, Eileen, et al.
Publicado: (2015)

Sentinel Lymph Node Biopsy in Pure DCIS: Is It Necessary?
por: Boler, D. E., et al.
Publicado: (2012)

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms
por: Drukker, C. A., et al.
Publicado: (2014)

Impact of analysis of the sentinel lymph node by one-step nucleic acid amplification (OSNA) compared to conventional histopathology on axillary and systemic treatment: data from the Dutch nationwide cohort of breast cancer patients
por: van Haaren, Elisabeth R. M., et al.
Publicado: (2023)

De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study
por: Simons, J. M., et al.
Publicado: (2020)

Mammographic screening detects low-risk tumor biology breast cancers
por: Drukker, C. A., et al.
Publicado: (2014)

Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands
por: Walstra, Coco J. E. F., et al.
Publicado: (2021)

Can late lymphoscintigraphy be omitted in the sentinel node procedure in early‐stage vulvar cancer?
por: Thissen, Daniek, et al.
Publicado: (2022)

Omitting Sentinel Lymph Node Biopsy in Elderly Patients: A Lost Opportunity?
por: Tuttle, Todd M., et al.
Publicado: (2021)

Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer
por: Moossdorff, M., et al.
Publicado: (2021)

Correction to: Omitting Sentinel Lymph Node Biopsy in Elderly Patients: A Lost Opportunity?
por: Tuttle, Todd M., et al.
Publicado: (2021)

The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening
por: van Luijt, P. A., et al.
Publicado: (2016)

Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
por: Wang, Xiaofang, et al.
Publicado: (2021)

Minimally invasive breast cancer excision using the breast lesion excision system under ultrasound guidance
por: Sanderink, W. B. G., et al.
Publicado: (2020)

Is palpable DCIS more aggressive than screen-detected DCIS?
por: Balac, Nina, et al.
Publicado: (2022)

Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists
por: Byng, Danalyn, et al.
Publicado: (2021)

Three-Dimensional Breast Radiotherapy and the Elective Radiation Dose at the Sentinel Lymph Node Site in Breast Cancer
por: van Roozendaal, Lori M., et al.
Publicado: (2015)

Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS
por: Bijker, N, et al.
Publicado: (2002)

The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07)
por: van Roozendaal, L. M., et al.
Publicado: (2015)

Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)
por: van Roozendaal, L. M., et al.
Publicado: (2017)

Microcalcification crystallography as a potential marker of DCIS recurrence
por: Gosling, Sarah B., et al.
Publicado: (2023)

Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers
por: Weigelt, B, et al.
Publicado: (2004)

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry
por: Meegdes, Marissa, et al.
Publicado: (2022)

Preoperative Nomogram for Predicting Sentinel Lymph Node Metastasis Risk in Breast Cancer: A Potential Application on Omitting Sentinel Lymph Node Biopsy
por: Hu, Xi’E, et al.
Publicado: (2021)

Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial
por: Raphael Daniela, D. B., et al.
Publicado: (2020)

Can Axillary Lymph Node Dissection Be Safely Omitted for Early-Stage Breast Cancer Patients with Sentinel Lymph Node Micrometastasis?
por: Damle, Sameer, et al.
Publicado: (2009)

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, S., et al.
Publicado: (2015)

Could axillary lymph node dissection be omitted in the mastectomy patient with tumor positive sentinel node?
por: You, Ji Young, et al.
Publicado: (2023)

Omitted Acknowledgment
Publicado: (2020)

Reference Omitted
Publicado: (2023)

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
por: Vriens, B. E. P. J., et al.
Publicado: (2017)

Clinical value of contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: a population-based cohort study
por: Keymeulen, Kristien B. I. M., et al.
Publicado: (2022)

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
por: Rakovitch, E., et al.
Publicado: (2018)

Active surveillance versus treatment in low-risk DCIS: Women’s preferences in the LORD-trial
por: Schmitz, Renée S.J.M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vu8vvv3phrhlnh0tog9m2tn4jn